Welcome to our dedicated page for Anika Therapeutics news (Ticker: ANIK), a resource for investors and traders seeking the latest updates and insights on Anika Therapeutics stock.
Anika Therapeutics, Inc. (NASDAQ: ANIK) is a global joint preservation company focused on early intervention orthopedics, osteoarthritis (OA) pain management, and regenerative solutions based on hyaluronic acid and implant technologies. This news page aggregates company-issued updates and market-moving announcements so readers can follow how Anika’s clinical programs, product portfolio, and financial performance evolve over time.
News about Anika commonly covers quarterly and annual financial results, including performance in its Commercial Channel and OEM Channel, as well as commentary on operating expenses, cost-saving measures, and capital allocation decisions such as share repurchase programs. Investors can also find updates on governance and compensation topics, including amendments to equity incentive plans and inducement grants made under Nasdaq Listing Rule 5635(c)(4).
A significant portion of Anika’s news flow focuses on clinical and regulatory milestones for its key products. Examples include updates on the U.S. pivotal Phase III FastTRACK study for the Hyalofast cartilage repair scaffold, the filing of the third and final PMA module for Hyalofast with the U.S. Food and Drug Administration, and progress toward a U.S. New Drug Application for Cingal, the company’s non-opioid, single-injection OA pain management product. Releases also describe commercial milestones, such as Cingal surpassing one million injections worldwide and the growth trajectory of the Integrity Implant System.
Corporate and leadership developments are another recurring theme. Anika issues press releases on planned leadership transitions, board changes, and strategic refocusing around its hyaluronic acid portfolio and regenerative solutions. By reviewing the ANIK news stream on this page, readers can monitor how clinical data, regulatory submissions, commercial performance, and governance actions shape the company’s position in osteoarthritis pain management and orthopedic regenerative medicine.
Anika (Nasdaq: ANIK) reported Q4 2025 revenue of $30.6M (flat YoY) and full‑year revenue of $112.8M (down 6% YoY). Q4 gross margin expanded to 63%; FY gross margin was 57%. Commercial Channel grew 22% Q4 and 15% FY. Adjusted EBITDA was $5.3M for FY 2025 and operating cash flow was $11.2M with $4.4M free cash flow. FDA provided PMA responses for Hyalofast in Jan 2026; company is preparing responses. 2026 guidance: revenue $114–$122.5M and adjusted EBITDA 5–10% of revenue. Company continues a $15M 10b5‑1 repurchase program.
Anika (NASDAQ: ANIK) announced that Steve Griffin, President and CEO, will present at the Canaccord Genuity 2026 Musculoskeletal Conference in New Orleans on March 2, 2026 at 11:30am CT / 12:30pm ET. Management will hold one-on-one investor meetings during the event.
The presentation will be webcast live on Anika's Events and Webcasts investor page and will be archived for 30 days. For meeting requests, contact investorrelations@anika.com.
Anika (NASDAQ: ANIK) will release its fourth quarter and year-end 2025 financial results before market open on Thursday, February 26, 2026.
A conference call to discuss results and business highlights will follow at 8:30 a.m. ET. Investors can join via dial-in, a live audio webcast, and an archived presentation on Anika's investor website.
Lumicell announced the appointment of Cheryl R. Blanchard, Ph.D. to its Board of Directors on February 4, 2026. Dr. Blanchard brings 30+ years of biotech and medtech leadership, will remain Executive Chair on Anika Therapeutics (NASDAQ: ANIK) board, and is a member of the National Academy of Engineering.
The company highlighted her commercial and regulatory experience as relevant to advancing LumiSystem™ adoption in surgical oncology.
Anika Therapeutics (NASDAQ: ANIK) announced a leadership transition effective February 1, 2026: Stephen (Steve) Griffin, currently Executive VP, Chief Financial Officer and Chief Operating Officer, will become President and Chief Executive Officer, and Cheryl R. Blanchard, Ph.D., will move to Executive Chair of the Board. John (Jack) B. Henneman, III was named Lead Independent Director and the company accepted the resignation of Susan N. Vogt from the board effective the same date. The release reconfirmed fiscal 2025 guidance. The company emphasized its strategic focus on hyaluronic acid, recent commercial momentum including double-digit growth in its commercial channel, the launch of the Integrity Implant System, and Griffin’s role in prior divestitures and operational improvements.
Anika (Nasdaq: ANIK) reported third-quarter 2025 revenue of $27.8M, down 6% year-over-year, with Commercial Channel +22% to $12.0M and OEM Channel -20% to $15.8M. Gross margin was 56%, operating expenses were $18.8M (down 3%), loss from continuing operations was $3.2M (loss of $0.22/share), and adjusted net income was $0.7M. Cash provided by operations was $6.9M and cash balance was $58.0M. Key corporate developments: final Hyalofast PMA module filed (Oct 31, 2025) with Phase III FastTRACK data released, progress on Cingal NDA studies, J&J MedTech extended Monovisc license through Dec 2031, and a $15M 10b5-1 share repurchase planned through June 2026.
Anika Therapeutics (NASDAQ: ANIK) filed the third and final PMA module for Hyalofast with the FDA on October 31, 2025, including 24-month FastTRACK Phase III data, post-hoc analyses, and real-world evidence. The randomized FastTRACK trial did not meet its pre-specified co-primary endpoints under the original statistical plan, but post-hoc observed-data analyses showed statistically significant superiority for Hyalofast on KOOS Pain (23.37% improvement; p=0.02) and several key secondary endpoints. Responder analyses favored Hyalofast at 10-, 15-, and 20-point KOOS Pain thresholds. The company cites COVID disruptions, imbalanced dropouts, and changing standard of care as drivers of the pre-specified outcome.
Anika (NASDAQ: ANIK) will issue its third quarter 2025 financial results before the market opens on Wednesday, November 5, 2025.
The company will hold a conference call at 8:30 a.m. ET to discuss results and business highlights; dial 1-800-717-1738 (U.S.) or 1-646-307-1865 (international) and use conference ID 53754. A live audio webcast and presentation materials will be available and archived in the Investor Relations section of www.anika.com.
Anika Therapeutics (NASDAQ: ANIK), a leader in osteoarthritis pain management and regenerative solutions, has granted inducement stock options to a new non-executive employee. The grant, made on September 2, 2025, consists of options to purchase 2,500 shares at an exercise price of $9.15 per share.
The options were granted under the company's 2021 Inducement Plan and will vest over three years, with one-third vesting annually. The options will expire after ten years and were granted as a material inducement for employment compensation, approved by the compensation committee under Nasdaq Listing Rule 5635(c)(4).
Anika Therapeutics (NASDAQ: ANIK) reported Q2 2025 financial results with mixed performance across segments. Revenue declined 8% to $28.2 million, with Commercial Channel revenue flat and OEM Channel revenue down 13%. The company's Regenerative Solutions revenue grew 41%, driven by strong performance of the Integrity™ Implant System and Hyalofast® growth.
Key developments include Hyalofast® clinical trial results which missed primary endpoints but showed significant improvements in secondary endpoints. The company plans to file the final PMA module in H2 2025. Anika maintained its fiscal 2025 guidance but revised long-term outlook, now expecting Commercial Channel growth of 10-20% in 2026-2027, down from previous 20-30%, due to anticipated Hyalofast launch delay to 2027.
The company resolved earlier production yield issues and received FDA clearance for new Integrity implant sizes. Operating expenses decreased 17%, while Q2 resulted in a loss from continuing operations of $4.6 million ($0.33 per share).